RxDoctor Payments Data

Michelle Morrison, NP

Family · Boydton, VANPI 1740734144

Payments from drug & device makers

$664in general payments, 2019–2025

Across 44 payments — averaging $15.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$236
  • Biogen$160
  • Argenx US, Inc.$64
  • Abbott$37
  • Eisai Inc.$36
  • AstraZeneca$28
  • plus $103 from 5 others

What the payments were for

  • Food & beverage$664100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$664 in reported general payments places this provider in the 60th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$1,678
Medicare patients
91
Services billed
250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin57$63,522
EliquisApixaban90$61,948
FarxigaDapagliflozin Propanediol56$59,763
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$42,481
XareltoRivaroxaban36$36,395
JanuviaSitagliptin Phosphate33$29,186
TradjentaLinagliptin28$23,790
RybelsusSemaglutide20$23,207
OzempicSemaglutide21$22,375
Breo ElliptaFluticasone/Vilanterol30$15,757
MyrbetriqMirabegron17$12,437
Lantus SolostarInsulin Glargine,hum.Rec.Anlog45$10,068
SymbicortBudesonide/Formoterol Fumarate16$7,994
Novolog FlexpenInsulin Aspart26$6,921
LantusInsulin Glargine,hum.Rec.Anlog24$5,768

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$28$67,75772 claims
Amneal Pharmaceuticals LLCUnithroid$24$2,03763 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,332 family providers in Virginia.

Other family in Boydton

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →